Загрузка...

Galectin-3: an immune checkpoint target for musculoskeletal tumor patients

In the past decade, the development of immune checkpoint inhibitors in oncological clinical settings was in the forefront. However, the interest in musculoskeletal tumor patients as candidates for checkpoint inhibition remains underserved. Here, we are forwarding evidence proposing that galectin-3 (...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Metastasis Rev
Главные авторы: Nakajima, Kosei, Balan, Vitaly, Raz, Avraham
Формат: Artigo
Язык:Inglês
Опубликовано: Springer US 2020
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7897198/
https://ncbi.nlm.nih.gov/pubmed/32929561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10555-020-09932-4
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!